Trials / Completed
CompletedNCT02121847
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cyclosporine 0.05% ophthalmic emulsion | Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months. |
| DRUG | carboxymethylcellulose-based lubricant eye drops | Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months. |
Timeline
- Start date
- 2014-04-03
- Primary completion
- 2014-09-23
- Completion
- 2014-09-23
- First posted
- 2014-04-24
- Last updated
- 2019-04-18
- Results posted
- 2016-04-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02121847. Inclusion in this directory is not an endorsement.